Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF 81 Debt-to-EBITDA is 0.37 as of Mar. 2026, which is 16% below its 10-year median of 0.44. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $14.23 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 83.93% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Wuxi AppTec Co's Debt-to-EBITDA or its related term are showing as below:
WUXIF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.28 Med: 0.44 Max: 1.72
Current: 0.33
During the past 12 years, the highest Debt-to-EBITDA Ratio of Wuxi AppTec Co was 1.72. The lowest was 0.28. And the median was 0.44.
WUXIF's Debt-to-EBITDA is ranked better than 83.93% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs WUXIF: 0.33
Wuxi AppTec Co (OTCPK:WUXIF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Wuxi AppTec Co Debt-to-EBITDA Related Terms
Wuxi AppTec Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Wuxi AppTec Co (WUXIF) has a Debt-to-EBITDA of 0.37 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Wuxi AppTec Co. This is 16% below median its historical median of 0.44. Over the past decade, Wuxi AppTec Co's Debt-to-EBITDA has ranged from 0.28 to 1.72. According to the industry distribution chart, Wuxi AppTec Co ranks #18 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 16.1%.
Is Wuxi AppTec Co's Debt-to-EBITDA too high?
Wuxi AppTec Co's current Debt-to-EBITDA of 0.37 is 16% below median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 1.72. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Wuxi AppTec Co's value of 0.37 is 84% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #18 out of 112 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #18 out of 112 companies for Debt-to-EBITDA. This places Wuxi AppTec Co in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.31. Wuxi AppTec Co's value of 0.37 is 84% below this benchmark. Historically, Wuxi AppTec Co's own Debt-to-EBITDA has ranged from 0.28 to 1.72 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 2.31, Wuxi AppTec Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Debt-to-EBITDA of 0.37 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Wuxi AppTec Co. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Debt-to-EBITDA is 0.37, which is 16% below median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.23, compared to a current price of $20.83 — trading 46.4% above its estimated fair value. The current Debt-to-EBITDA is 0.37, which is 16% below median its 10-year median of 0.44 and 84% below the Medical Diagnostics & Research industry median of 2.31. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Debt-to-EBITDA is 0.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $20.83 is trading 46.4% above its estimated GF Value™ of $14.23.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Debt-to-EBITDA: 0.37 (16% below median its 10-year median of 0.44)
GF Value™: $14.23 vs. price of $20.83 (46.4% above fair value)
Industry Position: 84% below the Medical Diagnostics & Research median (#18 of 112)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
